Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ferrer, a pharmaceutical company, has received an approval to initiate Phase III clinical trials of ozenoxacin formulated as a topical treatment for infectious dermatological conditions.
Subscribe to our email newsletter
According to the company, the multicenter, randomized study will start in February 2012 and are scheduled to complete in the first quarter of 2013.
The study, comparing ozenoxacin one percent cream versus placebo, will be conducted in about 465 patients up to two years old with a clinical diagnosis of non-bullous or bullous impetigo.
Ozenoxacin, a novel bactericidal second generation non-fluorinated quinolone, with a promising clinical efficacy, safety and tolerability profile, is available for licensing and commercialization from Ferrer.
Impetigo, a contagious bacterial skin infection, is most commonly found among infants, young children and those involved in close contact sports or living in enclosed environments.